Key facts
- Phagos’s last known valuation is $59.9M (Oct 2025).
- It has raised $31.9M across 1 recorded rounds; the latest was Seed Round ($1.5M) in Jul 2022.
- Notable investors include Bpifrance, Entrepreneurs First, AWS Startups, Agoranov, StartLife — 26 tracked in total.
- Phagos has filed 2 Form Ds with the SEC since 2022, most recently Nov 2024 ( sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Phagos
Funding rounds
1 roundsAbout Phagos
Operator of a biotechnology research company intended to provide customizable drugs to replace antibiotics in animal farming. The company uses a natural predator of bacteria that can constitute an efficient and sustainable alternative to antibiotics, enabling health professionals to overcome incurable and deadly infectious diseases.
- Sector
- Healthcare
- HQ
- Suresnes, France
- Founded
- 2021
- Employees
- 50
- Website
- phagos.org/
- Ownership
- Privately Held (backing)
Phagos doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phagos shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phagos in its N-PORT filings yet. We sweep new filings monthly.